2.31
+0.08
(3.42%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.24 - 2.32 |
| 52 week | 1.45 - 3.06 |
| Open | 2.28 |
| Vol / Avg. | 61,028.00/69,953.00 |
| Mkt cap | 68.72M |
| P/E | - |
| Div/yield | - |
| EPS | -0.18 |
| Shares | 29.80M |
| Beta | 1.40 |
| Inst. own | 1% |
Events
Apr 29, 2013
Prana Biotechnology Ltd. KPI Quarterly Report - March 2013
Mar 4, 2013
Prana Biotechnology Ltd. at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q2 (Jun '12) | 2012 | |
| Net profit margin | -113.01% | -207.30% |
| Operating margin | -113.01% | -207.30% |
| EBITD margin | - | -207.88% |
| Return on average assets | -49.95% | -64.08% |
| Return on average equity | -66.95% | -83.47% |
| Employees | 8 | - |
| Carbon Disclosure Rating | - | - |
Address
Level 2, 369 Royal Parade, Parkville
Parkville, VIC 3052
Australia
+61-3-93494906 (Phone)
+61-3-93480377 (Fax)
Parkville, VIC 3052
Australia
+61-3-93494906 (Phone)
+61-3-93480377 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Prana Biotechnology Limited (Prana) is development stage company. The Company is engaged in develop therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer�s disease. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company is also focusing on Huntington�s and Parkinson�s diseases. Other potential applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease and age-related cataracts.
Officers and directors
| Geoffrey Paul Kempler | Executive Chairman of the Board, Chief Executive Officer | |
| Richard Revelins | Chief Financial Officer, Company Secretary | |
| Dianne Angus | Chief Operating Officer | |
| Lawrence Gozlan | Non-Executive Independent Director | |
| Peter Ashley Marks | Non-Executive Independent Director | |
| Brian Derek Meltzer | Non-Executive Independent Director | |
| George William Mihaly | Non-Executive Independent Director |